The Alzheimer’s Disease Data Initiative (ADDI) is a coalition of leading academic, advocacy, government, industry, and philanthropy organisations that recognises the need for dementia researchers to find easier ways to share unpublished data, analytical tools, and scientific findings. These partners are working together to accelerate progress towards new diagnostics, treatments and cures in Alzheimer’s disease (AD) and related dementias.
In October 2023, ADDI organised an autumn learning series featuring talks on four datasets available on the AD Workbench. This is a secure, global, free platform for AD and related dementias researchers around the world to share data, resources, and tools. Attendees had the opportunity to learn about the background of these studies (i.e. relevant design details, recruitment criteria, original aims), any key findings to date, open questions or other ‘food for thought’ for ADDI users, and finally any tips, tricks or nuances to accessing the dataset. These moderated discussions were opened to all AD Connect members, the ADDI online community.
The third talk was given by David Vallez Garcia from the Department of Radiology and Nuclear Medicine at the Amsterdam UMC – VUMC (Netherlands). He presented the AMYPAD Consortium, the dataset of the AMYPAD Prognostic and Natural History Study and some results. This integrated dataset represents the largest European PET dataset phenotyping longitudinally individuals at risk of AD-related progression. The public dataset has been incorporated into the AD Workbench to provide even greater value to the global neuroscience research community.
If you miss the talk, a recording is available on AD Connect. Existing AD Workbench users already have access to AD Connect! If you are interested to register, visit the ADDI website: https://www.alzheimersdata.org/ad-connect